Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient
A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA resu...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry (Baltimore, Md.) Md.), 1996-04, Vol.42 (4), p.637-641 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 641 |
|---|---|
| container_issue | 4 |
| container_start_page | 637 |
| container_title | Clinical chemistry (Baltimore, Md.) |
| container_volume | 42 |
| creator | Van Duijnhoven, HL Pequeriaux, NC Van Zon, JP Blankenstein, MA |
| description | A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA result reported by Immulite was falsely low. For nine longitudinal samples, Immulite results were approximately 20-fold lower than the IMx value (range of IMx results 5-275 micrograms/L). A selection of the samples was analyzed with the ACS:180, ES-600, and IMx (all > 180 micrograms/L); Immulite, DPC Coat-A-Count IRMA, Immuno 1, AIA-pack, and Tandem-R (all |
| doi_str_mv | 10.1093/clinchem/42.4.637 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77990065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77990065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-29a66b27320378bfcacd155a999f64049a078ebe09a8139759c20d22fac029943</originalsourceid><addsrcrecordid>eNo9UcuO0zAUtRBo6Ax8AAskL4BdOnbiOPESjYBBqsQG1taNc50aOQ9sR1H_gY_GVUtXV1fncR-HkHec7TlT1aPxbjJHHB9FuRd7WTUvyI7XFSvaWvKXZMcYU4XionlN7mP8nVvRtPKO3LWS1bIVO_L3AGFA2rtoAi4wmRPtMG2IE13CHBMkLOKCxllnKEzJDRkJGFefIrVhHrPUWgw4JQoxwinSfg1uGqifp8GltXcTeGpn7-etWBc6Wwo3a2ryRAx0geSywxvyyoKP-PZaH8ivr19-Pj0Xhx_fvj99PhSmUm0qSgVSdmVTlaxq2s4aMD2va1BKWSmYUMCaFjtkClpeqaZWpmR9WVowrFRKVA_k08U37_FnxZj0mO9H72HCeY26aZRiTNaZyC9EkxeOAa1eghshnDRn-pyA_p-AFqUWOieQNe-v5ms3Yn9TXF-e8Q9XHKIBb0N-gYs3WnWOqD7TPl5oRzccNxdQxxG8z6Zcb9t2G_cPa8Kg_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77990065</pqid></control><display><type>article</type><title>Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient</title><source>Oxford University Press Journals</source><source>MEDLINE</source><creator>Van Duijnhoven, HL ; Pequeriaux, NC ; Van Zon, JP ; Blankenstein, MA</creator><creatorcontrib>Van Duijnhoven, HL ; Pequeriaux, NC ; Van Zon, JP ; Blankenstein, MA</creatorcontrib><description>A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA result reported by Immulite was falsely low. For nine longitudinal samples, Immulite results were approximately 20-fold lower than the IMx value (range of IMx results 5-275 micrograms/L). A selection of the samples was analyzed with the ACS:180, ES-600, and IMx (all > 180 micrograms/L); Immulite, DPC Coat-A-Count IRMA, Immuno 1, AIA-pack, and Tandem-R (all <70 micrograms/L); and Immulite free PSA assay (41 micrograms/L). Gel filtration demonstrated that apart from the alpha1-antichymotrypsin (ACT) complex, no other complexes were found. However, the sample consisted of 53% free PSA (IMx). Possibly, a change of conformation of the PSA molecule resulted in a decreased binding to ACT and a reduced affinity of the antibodies used in the affected assays.</description><identifier>ISSN: 0009-9147</identifier><identifier>EISSN: 1530-8561</identifier><identifier>DOI: 10.1093/clinchem/42.4.637</identifier><identifier>PMID: 8605684</identifier><identifier>CODEN: CLCHAU</identifier><language>eng</language><publisher>Washington, DC: Am Assoc Clin Chem</publisher><subject>Aged ; alpha 1-Antichymotrypsin - blood ; Biological and medical sciences ; False Negative Reactions ; Humans ; Immunoassay - statistics & numerical data ; Longitudinal Studies ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Clinical chemistry (Baltimore, Md.), 1996-04, Vol.42 (4), p.637-641</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-29a66b27320378bfcacd155a999f64049a078ebe09a8139759c20d22fac029943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3047854$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8605684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Duijnhoven, HL</creatorcontrib><creatorcontrib>Pequeriaux, NC</creatorcontrib><creatorcontrib>Van Zon, JP</creatorcontrib><creatorcontrib>Blankenstein, MA</creatorcontrib><title>Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient</title><title>Clinical chemistry (Baltimore, Md.)</title><addtitle>Clin Chem</addtitle><description>A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA result reported by Immulite was falsely low. For nine longitudinal samples, Immulite results were approximately 20-fold lower than the IMx value (range of IMx results 5-275 micrograms/L). A selection of the samples was analyzed with the ACS:180, ES-600, and IMx (all > 180 micrograms/L); Immulite, DPC Coat-A-Count IRMA, Immuno 1, AIA-pack, and Tandem-R (all <70 micrograms/L); and Immulite free PSA assay (41 micrograms/L). Gel filtration demonstrated that apart from the alpha1-antichymotrypsin (ACT) complex, no other complexes were found. However, the sample consisted of 53% free PSA (IMx). Possibly, a change of conformation of the PSA molecule resulted in a decreased binding to ACT and a reduced affinity of the antibodies used in the affected assays.</description><subject>Aged</subject><subject>alpha 1-Antichymotrypsin - blood</subject><subject>Biological and medical sciences</subject><subject>False Negative Reactions</subject><subject>Humans</subject><subject>Immunoassay - statistics & numerical data</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0009-9147</issn><issn>1530-8561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UcuO0zAUtRBo6Ax8AAskL4BdOnbiOPESjYBBqsQG1taNc50aOQ9sR1H_gY_GVUtXV1fncR-HkHec7TlT1aPxbjJHHB9FuRd7WTUvyI7XFSvaWvKXZMcYU4XionlN7mP8nVvRtPKO3LWS1bIVO_L3AGFA2rtoAi4wmRPtMG2IE13CHBMkLOKCxllnKEzJDRkJGFefIrVhHrPUWgw4JQoxwinSfg1uGqifp8GltXcTeGpn7-etWBc6Wwo3a2ryRAx0geSywxvyyoKP-PZaH8ivr19-Pj0Xhx_fvj99PhSmUm0qSgVSdmVTlaxq2s4aMD2va1BKWSmYUMCaFjtkClpeqaZWpmR9WVowrFRKVA_k08U37_FnxZj0mO9H72HCeY26aZRiTNaZyC9EkxeOAa1eghshnDRn-pyA_p-AFqUWOieQNe-v5ms3Yn9TXF-e8Q9XHKIBb0N-gYs3WnWOqD7TPl5oRzccNxdQxxG8z6Zcb9t2G_cPa8Kg_g</recordid><startdate>19960401</startdate><enddate>19960401</enddate><creator>Van Duijnhoven, HL</creator><creator>Pequeriaux, NC</creator><creator>Van Zon, JP</creator><creator>Blankenstein, MA</creator><general>Am Assoc Clin Chem</general><general>American Association for Clinical Chemistry</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960401</creationdate><title>Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient</title><author>Van Duijnhoven, HL ; Pequeriaux, NC ; Van Zon, JP ; Blankenstein, MA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-29a66b27320378bfcacd155a999f64049a078ebe09a8139759c20d22fac029943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Aged</topic><topic>alpha 1-Antichymotrypsin - blood</topic><topic>Biological and medical sciences</topic><topic>False Negative Reactions</topic><topic>Humans</topic><topic>Immunoassay - statistics & numerical data</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Duijnhoven, HL</creatorcontrib><creatorcontrib>Pequeriaux, NC</creatorcontrib><creatorcontrib>Van Zon, JP</creatorcontrib><creatorcontrib>Blankenstein, MA</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Duijnhoven, HL</au><au>Pequeriaux, NC</au><au>Van Zon, JP</au><au>Blankenstein, MA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient</atitle><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle><addtitle>Clin Chem</addtitle><date>1996-04-01</date><risdate>1996</risdate><volume>42</volume><issue>4</issue><spage>637</spage><epage>641</epage><pages>637-641</pages><issn>0009-9147</issn><eissn>1530-8561</eissn><coden>CLCHAU</coden><abstract>A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA result reported by Immulite was falsely low. For nine longitudinal samples, Immulite results were approximately 20-fold lower than the IMx value (range of IMx results 5-275 micrograms/L). A selection of the samples was analyzed with the ACS:180, ES-600, and IMx (all > 180 micrograms/L); Immulite, DPC Coat-A-Count IRMA, Immuno 1, AIA-pack, and Tandem-R (all <70 micrograms/L); and Immulite free PSA assay (41 micrograms/L). Gel filtration demonstrated that apart from the alpha1-antichymotrypsin (ACT) complex, no other complexes were found. However, the sample consisted of 53% free PSA (IMx). Possibly, a change of conformation of the PSA molecule resulted in a decreased binding to ACT and a reduced affinity of the antibodies used in the affected assays.</abstract><cop>Washington, DC</cop><pub>Am Assoc Clin Chem</pub><pmid>8605684</pmid><doi>10.1093/clinchem/42.4.637</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9147 |
| ispartof | Clinical chemistry (Baltimore, Md.), 1996-04, Vol.42 (4), p.637-641 |
| issn | 0009-9147 1530-8561 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77990065 |
| source | Oxford University Press Journals; MEDLINE |
| subjects | Aged alpha 1-Antichymotrypsin - blood Biological and medical sciences False Negative Reactions Humans Immunoassay - statistics & numerical data Longitudinal Studies Male Medical sciences Nephrology. Urinary tract diseases Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Tumors of the urinary system Urinary tract. Prostate gland |
| title | Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T21%3A48%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Large%20discrepancy%20between%20prostate-specific%20antigen%20results%20from%20different%20assays%20during%20longitudinal%20follow-up%20of%20a%20prostate%20cancer%20patient&rft.jtitle=Clinical%20chemistry%20(Baltimore,%20Md.)&rft.au=Van%20Duijnhoven,%20HL&rft.date=1996-04-01&rft.volume=42&rft.issue=4&rft.spage=637&rft.epage=641&rft.pages=637-641&rft.issn=0009-9147&rft.eissn=1530-8561&rft.coden=CLCHAU&rft_id=info:doi/10.1093/clinchem/42.4.637&rft_dat=%3Cproquest_cross%3E77990065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77990065&rft_id=info:pmid/8605684&rfr_iscdi=true |